S. Vincent Rajkumar

Dec 4, 2024 | nature.com | S. Vincent Rajkumar |Maria-Victoria Mateos

AbstractThis study aimed to provide real-world evidence on progression risk in patients with high-risk smoldering multiple myeloma (SMM). This retrospective, observational study leveraged data from the Flatiron Health database. Eligible patients had SMM and relevant measures to apply Mayo 2018, International Myeloma Working Group (IMWG) 2020, and AQUILA trial risk criteria.

Aug 11, 2024 | nature.com | Charlotte Pawlyn |Fredrik Schjesvold |David Cairns |Maria-Victoria Mateos |Jacob P. Laubach |Katja Weisel | +4 more

AbstractMeasurement of overall survival (OS) remains the gold standard for interpreting the impact of new therapies for multiple myeloma in phase 3 trials. However, as outcomes have improved, it is increasingly challenging to use OS as the primary endpoint if timely approval of novel agents is to be ensured to enable maximum benefit for patients.

Jul 22, 2024 | nature.com | Matthew Rees |Radhika Bansal |Sikander Ailawadhi |Ricardo D. Parrondo |Saurabh Chhabra |Angela Dispenzieri | +9 more

AbstractThree classes of BCMA-directed therapy (BDT) exist: antibody drug-conjugates (ADCs), CAR-T, and T-cell engagers (TCEs), each with distinct strengths and weaknesses. To aid clinicians in selecting between BDTs, we reviewed myeloma patients treated at Mayo Clinic with commercial or investigational BDT between 2018-2023.

Jun 29, 2024 | onlinelibrary.wiley.com | S. Vincent Rajkumar

1 DISEASE OVERVIEW Multiple myeloma accounts for 1% of all cancers and approximately 10% of all hematologic malignancies.1 Each year over 35 000 new cases are diagnosed in the United States, and almost 13 000 patients die of the disease.2 The annual age-adjusted incidence in the United States has remained stable for decades at approximately four per 100000.3 Multiple myeloma is slightly more common in men than in women, and is twice as common in African-Americans compared with Caucasians.4...

May 17, 2024 | onclive.com | S. Vincent Rajkumar

S. Vincent Rajkumar, MD, professor, medicine, Mayo Clinic College of Medicine, chair, Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group, discusses highly anticipated abstracts in multiple myeloma that will be presented at the 2024 ASCO Annual Meeting.